Abstract Details

Title Cancer informatics survey of different grades and subtypes of glioma

Topic Neuro-oncology

Presentation(s) P14 - Poster Session 14 (11:45 AM-12:45 PM)

Poster/Presentation
Number 4-003

Objective This work aims to investigate the molecular trajectories of different grades of glioma to see how similar they are using a cancer informatics framework. We hypothesize that such a data-driven approach may aid in the discovery of new drug targets and miRNA that can potentially regulate tumor formation, which may benefit treatment and prognosis studies.

Background Gliomas are brain tumors that originate in the glial cells. "Glioma" is a blanket term used for defining various kinds of glial tumors, including astrocytoma, oligodendroglioma, and glioblastoma. The aggressiveness or malignancy of gliomas varies. While some are slow-growing and potentially treatable, others are invasive, proliferative, and tend to recur.

Design/Methods We have used a translational bioinformatics approach to proceed with the investigation. We used the Disgenet database to retrieve canonical disease gene sets (18 diseases), including three WHO (World Health Organization) grade-wise tumors and eight WHO grade-wise subtypes of Diffuse astrocytic and oligodendroglia tumors, five other astrocytic tumors, and two high and low-grade tumor datasets.

Results Enrichr-based pathway enrichment analysis revealed Viral myocarditis, Hepatitis B and C, Malaria, Measles, Influenza, Tuberculosis, and Alcoholism were enriched across different sub-types. STRING-db was used to compute protein networks using graph-based metrics, and critical genes such as LRRC59, CCDC67, TRMT11, and TMEM135 were identified in Glioblastoma multiforme, while Cytoscape was used to prioritize candidates. cBioPortal was used to analyse datasets in order to find racial, gender and age disparities in CNS tumors.

Conclusions Further evaluation of these targets could lead to identifying shared and distinct pathways associated with gliomas that could be targeted to develop new treatment approaches.

Authors/Disclosures
Parampreet Kaur, MS (RAMAIAH UNIVERSITY OF APPLIED SCIENCES) PRESENTER	Ms. Kaur has nothing to disclose.

��ɫ��

��ɫ��